Menu
Recruiting NCT07130981

Body Composition and Psychosocial Factors in ICI-Treated Cancer Patients

Observational Cancer Psychosocial Functioning Treatment Side Effects Cachexia

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Cancer, Psychosocial Functioning, Treatment Side Effects, Cachexia. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Turkey (Türkiye)
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Evaluation of Body Composition, Psychosocial Factors, and Drug-Related Problems in Relation to Clinical Progression in Cancer Patients Receiving Immune Checkpoint Inhibitors

Overview

Evaluation of the effects of body composition, psychosocial factors, and drug-related problems on clinical progression (such as toxicity, treatment response, and quality of life) in cancer patients treated with immune checkpoint inhibitors

Primary outcome measures

  • Body composition evaluation [Time frame: Patient recruitment is planned to occur over a 6-month period. Each participant will be followed for a maximum duration of 6 months from the initiation of immunotherapy.]
Secondary outcome measures (2)
  • Cachexia and psychosocial factors evaluation [Time frame: Throughout 6 months of follow-up.]
  • Drug Related Problems [Time frame: Throughout 6 months of follow-up.]

Eligibility criteria

Inclusion criteria

  • Aged 18 years or older
  • Having undergone a CT scan (at the L3 level) prior to treatment
  • No severe mental disorder and able to communicate effectively
  • Provided written informed consent

Exclusion criteria

  • Did not provide written informed consent
  • Patients deemed unsuitable by the physician

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Turkey (Türkiye) · 1 center
  • Hacettepe University Faculty of Pharmacy, Department of Clinical Pharmacy — Ankara

Identifiers

NCT: NCT07130981 · SBA 25/672

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗